The effect on the coagulation and fibrinolytic systems of various factor IX concentrates after addition of heparin, antithrombin III or Trasylol to the concentrate before infusion into dogs was studied in an attempt to characterize the clot-promoting activity or activities in these concentrates. After infusion of Preconativ (AB Kabi; 100 u factor IX/kg bodyweight) only small decreases of fibrinogen and platelet count in the samples taken 1 and 4 hrs after infusion were found. Addition of heparin (10 u/ml; 5 dogs) or Trasylol (40 u/u factor IX initially followed by 10,000 u/h; 3 dogs) had no effect but addition of antithrombin III (100 u/kg; 3 dogs) prevented all changes. Infusion of Konyne (Cutter Laboratories; 100 u/kg bodyweight) induced marked decreases of both fibrinogen and the platelet count at 1, 4 and 24 hrs after infusion and the ethanol gelation test became positive. Addition of heparin (10 u/ml; 5 dogs) diminished the changes but did not completely counteract them. Antithrombin III (100 u/kg; 3 dogs) added to the concentrate before infusion also reduced the induced changes to about the same extent as heparin. Trasylol (40 u/u factor IX initially followed by 10,000 u/h; 3 dogs) did not seem to have any effect. Addition of both antithrombin III and Trasylol (4 dogs) did, however, prevent almost all changes.
It is thus obvious that the two commercial factor IX concentrates used may contain clot promoting activities and that these activities may differ between various concentrates.
References
1
Blatt PM,
Lundblad RL,
Kingdon HS,
McLean G,
Roberts HR.
1974; Thrombogenic materials in prothrombin complex concentrates. Annals of Internal Medicine 81: 766
2
Cederbaum AI,
Blatt PM,
Roberts H.
1976; Intravascular coagulation with use of human prothrombin complex concentrates. Annals of Internal Medicine 84: 683
5
Fagerhol MK,
Abildgaard U.
1970; Immunological studies on human antithrombin III. Influence of age, sex and use of oral contraceptives on serum concentration Scandinavian Journal of Haematology 7: 10
8
Hedner U,
Nilsson IM,
Bergentz S-E.
1976; Various prothrombin complex concentrates and their effect on coagulation and fibrinolysis in vivo. Thrombosis and Haemostasis 35: 386
12
Latallo ZS,
Wegrzynowicz E,
Teisseyre E,
Kopec M.
1970; Simple and rapid evaluation of the intravascular coagulation and fibrinolytic status by application of protamine sulphate and Reptilase. Scandinavian Journal of Haematology, Suppl 13: 387
13
Leandoer L,
Bergentz S-E,
Nilsson IM.
1968; Coagulation factors and components of the fibrinolytic system in lymph and blood in dogs. Thrombosis et Diathesis Haemorrhagica 19: 129
14
MéNaché D,
Guillin MC.
1975; The use of factor IX concentrates for patients with conditions other than factor IX deficiency. British Journal of Haematology Suppl 31: 247
16
Niléhn J-E.
1967; Separation and estimation of “split products” of fibrinogen and fibrin in human serum. Thrombosis et Diathesis Haemorrhagica 18: 487
20
Nilsson IM,
Hedner U,
Bjorlin G.
1973; Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide. Annals of Internal Medicine 78: 91
22
Paraskevas M,
Nilsson IM,
Martinsson G.
1962; A method for determining serum inhibitors of plasminogen activation. Scandinavian Journal of Clinical and Laboratory Investigation 14: 138
24
Pepper DS,
Banhegyi D,
Howie A.
1977; a Spectrophotometric determination of factor Xa generation in factor IX concentrates. Thrombosis and Haemostasis 37: 535
25
Sakuragawa N,
Takahashi K,
Hoshiyama M,
Nirya K,
Itoh M,
Matsuoko M,
Ohniski Y.
1977; Characteristics and thrombogenicity of prothrombin complex concentrates. Thrombosis Research 1: 315
26
Sas G,
Owens RE,
Smith JK,
Middleton S,
Cash J.
1975; In vitro spontaneous thrombin generation in human factor IX concentrates. British Journal of Haematology 31: 25
27
Smith JK,
Snape TJ,
Bidwell E,
Edwards R,
Gunson HH.
1977; Preparation of factor IX concentrate from platelet-rich plasma. Thrombosis and Haemostasis 37: 363
29
Vermylen J,
Schetz J,
Semeraro N,
Verstraete M.
1976; Clinical and laboratory experience with fraction R: Attempts at identifying the active principle. Workshop on Inhibitors of Factors VIII and IX (Facultas-Verlag, Wien), Wien, Jan. 26-26 p 110
